Flex Pharma, Inc. (Nasdaq: FLKS) announced that it has initiated a human proof-of-concept efficacy study in nocturnal leg cramps (NLC) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE